Recent status of drug-induced liver injury and its problems in Japan

Japan Medical Association Journal

Volumn 53, Issue 4, 2010, Pages 243-247

  Takikawa, Hajime ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Causal drug; Diagnostic criteria; Dietary supplement; Drug induced lymphocyte stimulation test (DLST)

Indexed keywords

ANALGESIC AGENT; ANTIALLERGIC AGENT; ANTIANEMIC AGENT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; GASTROINTESTINAL AGENT; GLYCYRRHIZIC ACID; HERBACEOUS AGENT; HORMONE; PHENOBARBITAL; PREDNISOLONE; URSODEOXYCHOLIC ACID;

ADVERSE OUTCOME; CAUSAL ATTRIBUTION; CLINICAL FEATURE; CONTINUOUS HEMODIAFILTRATION; DIET SUPPLEMENTATION; DISEASE CLASSIFICATION; DISEASE DURATION; HEALTH STATUS; HEALTH SURVEY; HEMODIALYSIS; HUMAN; INTRAHEPATIC CHOLESTASIS; JAPAN; LIVER CELL DAMAGE; LIVER FUNCTION TEST; REVIEW; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT INDICATION; TREND STUDY;

EID: 77958464730     PISSN: 13468650     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. A proposal of diagnostic criteria of drug-induced liver injury. In: Proceeding of the Third Drug and Liver Meeting. Tokyo: Toryo Printing Co., Ltd.; 1978:96-98. (in Japanese)
2. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323-1330.
3. Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res. 2003;27:192-195.
4. Takikawa H, Takamori Y, Hisamochi A, et al. A proposal of new diagnostic criteria for drug-induced liver injury-based on the revisions of the diagnostic criteria by the international consensus meetings. Kanzo. 2003;44:176-179. (in Japanese)
5. Takikawa H, Onji M, Takamori Y, et al. Proposal of diagnostic criteria for drug-induced liver injury revised by the DDW-J 2004 Workshop. Kanzo. 2005;46:85-90. (in Japanese)
6. Takikawa H, Onji M. A proposal of the diagnostic scale of druginduced liver injury. Hepatol Res. 2005;32:250-251.
7. Horiike N, Murata Y, Takikawa H, et al. Present status of druginduced liver injury-national survey. In: Onji M, editor-in-chief; Takikawa H, Horiike N, Fukui H, eds. Present Status of Druginduced Liver Injury. Tokyo: Chugai-Igakusha; 2008:1-10. (in Japanese)
8. Takikawa H, Murata Y, Horiike N, et al. Drug-induced liver injury in Japan: An analysis of 1,676 cases between 1997 and 2006. Hepatol Res. 2009;39:427-431.
9. Tameda Y, Adachi Y, Watanabe A. National survey of druginduced liver injury. In: Watanabe A, Higuchi K, eds. Newest Hepatology-from National Status Survey to Future Prospects. Tokyo: Shinko-Igaku; 2001:50-61. (in Japanese)
10. Takikawa H. Until what levels of hepatobiliary enzymes may we continue medication when the causal drug is the key drug (for concomitant disease in the same patient)? In: Atomi Y, Uemura N, Shiratori K, et al., eds. Clinically Relevant Evidence for the Treatment of Hepatic/Biliary/Pancreatic Diseases. Tokyo: Bunkodo; 2007:116-117. (in Japanese)
11. Takikawa H. Recent status of drug-induced liver injury. Hepatol Res. 2009;39:1-6.